Sema4 appoints Dr. Rachel Sherman to its Board of Directors

– USA, CT –  Sema4, a patient-centered health intelligence company, today announced the appointment of Rachel Sherman, MD, MPH, former Principal Deputy Commissioner of Food and Drugs at the U.S. Food and Drug Administration, to its Board of Directors.

“Rachel’s extraordinary track record in medical policy, regulation and patient advocacy adds an important perspective to our Board of Directors,” said Eric Schadt, PhD, Founder and CEO. “We are honored that she has joined the Sema4 team and we are looking forward to working with her as Sema4 continues its growth as a leader in precision medicine and patient-centered health intelligence.”

In addition to Dr. Sherman, Sema4’s Board of Directors includes:

  • Dr. Dennis Charney, Dean of the Icahn School of Medicine at Mount Sinai;
  • Dr. Kenneth Davis, President and CEO of the Mount Sinai Health System;
  • Viral Patel, Senior Managing Director in the Tactical Opportunities Group at Blackstone;
  • Dr. Michael Pellini, Managing Partner of Section 32;
  • Joshua Ruch, co-founder and Chief Executive Officer of Rho Capital Partners and Trustee of the Mount Sinai Health System;
  • David Windreich, Managing Partner and Founder of Cypress Forest Holdings, LLC and Trustee of the Mount Sinai Health System;
  • Dr. Schadt.

About Dr. Sherman

Dr. Sherman spent nearly 30 years with the FDA, serving most recently as Principal Deputy Commissioner of Food and Drugs, the most senior career position at the Agency. In this role, she was responsible for cross-cutting clinical policy and programs, overseeing approximately 2,000 employees and a budget of more than $500 million. During her distinguished career at the FDA, Dr. Sherman spearheaded HIV drug development during the height of the AIDS crisis, directed the Critical Path Initiative, launched the expedited review, development and breakthrough designation programs, and guided the establishment of the Oncology Center of Excellence (OCE), the Sentinel Initiative and the Evidence Generation program.

Dr. Sherman is currently the President and Founding Partner of Rachel Sherman Partners, LLC, through which she applies her expertise in regulatory science and medical product evaluation to address client challenges at all stages of product development. She also serves as a faculty member in the Department of Population Health, Harvard Pilgrim Health Care, Harvard University. Dr. Sherman earned an AB in mathematics from Washington University in St. Louis, an MD from Mount Sinai School of Medicine, and an MPH from Johns Hopkins University.

“Accelerating precision medicine is critical for public health, and I believe that Sema4 has the team, talent, and a clearly demonstrated commitment to bring real value to patients,” said Dr. Sherman. “I am delighted to have the opportunity to work closely with the Sema4 team as they continue to deliver novel clinical insights in support of better patient outcomes in cancer and women’s health.”

About Sema4

Sema4 is a patient-centered health intelligence company founded on the idea that more information, deeper analysis, and increased engagement will improve the diagnosis, treatment, and prevention of disease. Sema4 is dedicated to transforming healthcare by building dynamic models of human health and defining optimal, individualized health trajectories, starting in the areas of reproductive health and oncology. Centrellis, our innovative health intelligence platform, is enabling us to generate a more complete understanding of disease and wellness and to provide science-driven solutions to the most pressing medical needs. Sema4 believes that patients should be treated as partners, and that data should be shared for the benefit of all.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.